Background: Milrinone has been suggested as a possible first-line therapy for preterm neonates to prevent postligation cardiac syndrome (PLCS) through decreasing systemic vascular resistance and increasing cardiac contractility. The optimal dosing regimen, however, is not known. Objective: To model the dosing of milrinone in preterm infants for prevention of PLCS after surgical closure of patent ductus arteriosus (PDA). Methods: Milrinone time-concentration profiles were simulated for 1,000 subjects using the volume of distribution and clearance estimates based on one compartmental population pharmacokinetic model by Paradisis et al. [Arch Dis Child Fetal Neonatal Ed 2007;92:F204-F209]. Dose optimization was based on retrospectively collected demographic data from neonates undergoing PDA ligation in Estonian PICUs between 2012 and 2014 and existing pharmacodynamic data. The target plasma concentration was set at 150-200 ng/ml. Results: The simulation study used demographic data from 31 neonates who underwent PDA ligation. The median postnatal age was 13 days (range: 3-29) and weight was 760 g (range: 500-2,351). With continuous infusion of milrinone 0.33 μg/kg/min, the proportion of subjects within the desired concentration range was 0% by 3 h, 36% by 6 h, and 61% by 8 h; 99% of subjects exceeded the range by 18 h. The maximum proportion of total simulated concentrations in the target range was attained with a bolus infusion of 0.73 μg/kg/min for 3 h followed by a 0.16-μg/kg/min maintenance infusion. Conclusion: Mathematical simulations suggest that in preterm neonates the plasma time-concentration profile of milrinone can be optimized with a slow loading dose followed by maintenance infusion.

Keywords:
Milrinone, Patent ductus arteriosus, Postligation cardiac syndrome
1.
McNamara PJ, Stewart L, Shivananda SP, Stephens D, Sehgal A: Patent ductus arteriosus ligation is associated with impaired left ventricular systolic performance in premature infants weighing less than 1,000 g. J Thorac Cardiovasc Surg 2010;140:150-157.
2.
Noori S, Friedlich P, Seri I, Wong P: Changes in myocardial function and hemodynamics after ligation of the ductus arteriosus in preterm infants. J Pediatr 2007;150:597-602.
3.
Jain A, Sahni M, El-Khuffash AF, Khadawardi E, Sehgal A, McNamara PJ: Use of targeted neonatal echocardiography to prevent postoperative cardiorespiratory instability after patent ductus arteriosus ligation. J Pediatr 2012;160:584-589.
4.
Ramamoorthy C, Anderson GD, Williams GD, Williams GD, Lynn AM: Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. Anesth Analg 1998;86:283-289.
5.
Zuppa AF, Nicolson SC, Adamson PC, Wernovsky G, Mondick JT, Burnham N, Hoffman TM, Gaynor JW, Davis LA, Greeley WJ, Spray TL, Barrett JS: Population pharmacokinetics of milrinone in neonates with hypoplastic left heart syndrome undergoing stage I reconstruction. Anesth Analg 2006;102:1062-1069.
6.
Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, Bailey JM, Akbary A, Kocsis JF, Kaczmarek R, Spray TL, Wessel DL: Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003;107:996-1002.
7.
Vogt W: Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model. Clin Pharmacokinet 2014;53:51-72.
8.
Paradisis M, Jiang X, McLachlan AJ, Evans N, Kluckow M, Osborn D: Population pharmacokinetics and dosing regimen design of milrinone in preterm infants. Arch Dis Child Fetal Neonatal Ed 2007;92:F204-F209.
9.
R Core Team: R: A Language and Environment for Statistical Computing. Vienna, R Foundation for Statistical Computing, 2014. http://www.R-project.org/.
10.
El-Khuffash AF, Jain A, Weisz D, Mertens L, McNamara PJ: Assessment and treatment of post patent ductus arteriosus ligation syndrome. J Pediatr 2014;165:46-52.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.